These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

92 related articles for article (PubMed ID: 23631206)

  • 1. [Dyslipidemia].
    Kihara S
    Nihon Rinsho; 2013 Feb; 71(2):275-9. PubMed ID: 23631206
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Overproduction of very low-density lipoproteins is the hallmark of the dyslipidemia in the metabolic syndrome.
    Adiels M; Olofsson SO; Taskinen MR; Borén J
    Arterioscler Thromb Vasc Biol; 2008 Jul; 28(7):1225-36. PubMed ID: 18565848
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Lipid and lipoprotein dysregulation in insulin resistant states.
    Avramoglu RK; Basciano H; Adeli K
    Clin Chim Acta; 2006 Jun; 368(1-2):1-19. PubMed ID: 16480697
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Circulating very-low-density lipoprotein characteristics resulting from fatty liver in an insulin resistance rat model.
    Zago V; Lucero D; Macri EV; Cacciagiú L; Gamba CA; Miksztowicz V; Berg G; Wikinski R; Friedman S; Schreier L
    Ann Nutr Metab; 2010; 56(3):198-206. PubMed ID: 20203480
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Combined effects of rosiglitazone and conjugated linoleic acid on adiposity, insulin sensitivity, and hepatic steatosis in high-fat-fed mice.
    Liu LF; Purushotham A; Wendel AA; Belury MA
    Am J Physiol Gastrointest Liver Physiol; 2007 Jun; 292(6):G1671-82. PubMed ID: 17322064
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Catabolism of lipoproteins and metabolic syndrome.
    Therond P
    Curr Opin Clin Nutr Metab Care; 2009 Jul; 12(4):366-71. PubMed ID: 19474714
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Enhanced expression of hepatic acyl-coenzyme A synthetase and microsomal triglyceride transfer protein messenger RNAs in the obese and hypertriglyceridemic rat with visceral fat accumulation.
    Kuriyama H; Yamashita S; Shimomura I; Funahashi T; Ishigami M; Aragane K; Miyaoka K; Nakamura T; Takemura K; Man Z; Toide K; Nakayama N; Fukuda Y; Lin MC; Wetterau JR; Matsuzawa Y
    Hepatology; 1998 Feb; 27(2):557-62. PubMed ID: 9462657
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Ces3/TGH deficiency improves dyslipidemia and reduces atherosclerosis in Ldlr(-/-) mice.
    Lian J; Quiroga AD; Li L; Lehner R
    Circ Res; 2012 Sep; 111(8):982-90. PubMed ID: 22872154
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Glycine normalizes hepatic triglyceride-rich VLDL secretion by triggering the CNS in high-fat fed rats.
    Yue JT; Mighiu PI; Naples M; Adeli K; Lam TK
    Circ Res; 2012 May; 110(10):1345-54. PubMed ID: 22474253
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Adipose tissue dysfunction in obesity.
    Blüher M
    Exp Clin Endocrinol Diabetes; 2009 Jun; 117(6):241-50. PubMed ID: 19358089
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Lipodystrophy: lessons in lipid and energy metabolism.
    Simha V; Garg A
    Curr Opin Lipidol; 2006 Apr; 17(2):162-9. PubMed ID: 16531753
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Molecular evidence supporting the portal theory: a causative link between visceral adiposity and hepatic insulin resistance.
    Kabir M; Catalano KJ; Ananthnarayan S; Kim SP; Van Citters GW; Dea MK; Bergman RN
    Am J Physiol Endocrinol Metab; 2005 Feb; 288(2):E454-61. PubMed ID: 15522994
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Regulation of plasma triglycerides in insulin resistance and diabetes.
    Ginsberg HN; Zhang YL; Hernandez-Ono A
    Arch Med Res; 2005; 36(3):232-40. PubMed ID: 15925013
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Very low density lipoprotein and low density lipoprotein isolated from patients with hepatitis C infection induce altered cellular lipid metabolism.
    Napolitano M; Giuliani A; Alonzi T; Mancone C; D'Offizi G; Tripodi M; Bravo E
    J Med Virol; 2007 Mar; 79(3):254-8. PubMed ID: 17245726
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Obesity and dyslipidemia.
    Franssen R; Monajemi H; Stroes ES; Kastelein JJ
    Med Clin North Am; 2011 Sep; 95(5):893-902. PubMed ID: 21855698
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Fatty liver disease in obese children--relation to other metabolic risk factors.
    Volovelsky O; Weiss R
    Int J Pediatr Obes; 2011 Sep; 6 Suppl 1():59-64. PubMed ID: 21905818
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Human resistin stimulates hepatic overproduction of atherogenic ApoB-containing lipoprotein particles by enhancing ApoB stability and impairing intracellular insulin signaling.
    Costandi J; Melone M; Zhao A; Rashid S
    Circ Res; 2011 Mar; 108(6):727-42. PubMed ID: 21293001
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A role for hepatic leptin signaling in lipid metabolism via altered very low density lipoprotein composition and liver lipase activity in mice.
    Huynh FK; Neumann UH; Wang Y; Rodrigues B; Kieffer TJ; Covey SD
    Hepatology; 2013 Feb; 57(2):543-54. PubMed ID: 22941940
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pathophysiology of dyslipidemia in Cushing's syndrome.
    Arnaldi G; Scandali VM; Trementino L; Cardinaletti M; Appolloni G; Boscaro M
    Neuroendocrinology; 2010; 92 Suppl 1():86-90. PubMed ID: 20829625
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Dyslipidemia and abdominal obesity: mechanisms and characteristics (Part I)].
    Farnier M
    Arch Mal Coeur Vaiss; 2007 Dec; 100(12):979-84. PubMed ID: 18223510
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.